G-protein coupled receptors (GPCRs) respond to a chemically diverse plethora of signal transduction molecules. The notion that GPCRs also signal without an external chemical trigger, i.e. in a constitutive or spontaneous manner, resulted in a paradigm shift in the field of GPCR pharmacology. With the recognition of constitutive GPCR activity and the fact that GPCR binding and signaling can be strongly affected by a single point mutation, GPCR pharmacogenomics obtained a lot of attention. For a variety of GPCRs, point mutations have been convincingly linked to human disease. Mutations within conserved motifs, known to be involved in GPCR activation, might explain the properties of some naturally occurring constitutively active GPCR variants linked to disease. A brief history historical introduction to the present concept of constitutive receptor activity is given and the pharmacogenomic and the structural aspects of constitutive receptor activity are described.
Introduction
G-protein coupled receptors (GPCRs) form one of the most versatile families of proteins to respond to the chemically diverse plethora of signal transduction molecules. Hence, for many years this receptor family has been subject of study for human therapeutic benefit.
Many top-selling drugs from the past and present target the membrane bound GPCRs and the pipelines of most pharmaceutical industries are filled with GPCR-targeting molecules. With the notion that GPCRs can also signal without an external chemical trigger, i.e. in a constitutive or spontaneous manner, a paradigm shift in the field of GPCR pharmacology was recently initiated. In this overview we aim to give a brief historical introduction to the development of the present concept of constitutive receptor activity, whereafter we will indicate the importance of constitutive GPCR activity in relation to the present ideas on the structural basis of GPCR (de)activation and to human GPCR pharmacogenomics.
Early receptor concepts and the molecular basis of drug action.
GPCRs have been subject of study since the early days of pharmacology and many of these investigations have been instrumental to the development of modern concepts of receptor theory. The term receptors was initially introduced by Langley (1) and Ehrlich (2) to explain the action of respectively nicotine and toxins. Applying the 'lock -key' model as introduced by Emil Fischer (3) , for describing the enzyme-substrate interactions in biochemistry, the founders of early pharmacology suggested 'receptive substances' to exist in order to explain the biological actions of exogenous chemicals on cells. This concept matured with the seminal contribution of Clark, stating that the effect of an agonist is proportional to the number of occupied receptors. His occupancy theory (4, 5) also readily accommodated the difference between an agonist and an antagonist, following the 'lock -key' principle of Fischer.
In the 1960s Ariëns and co-workers published their well-known book "Molecular Pharmacology" (6) , in which the work of Clark was extended. Ariëns et al introduced the concept intrinsic activity to explain the observation that not every agonist of a given receptor induced the same maximum effect. Compounds reaching the maximum were referred to full agonist (intrinsic activity is 1) and other agonists were named partial agonist, having an intrinsic activity between 0 and 1. Competitive antagonists were supposed to have an affinity for the receptor, but to posses an intrinsic activity of 0. The Clark-Ariëns model was extended first by Stephenson (7) and later Furchgott (8, 9) with the introduction of drug efficacy and the system-independent concept of intrinsic efficacy.
The developed concepts have had a great impact in the area of pharmacology and drug discovery, especially as the mathematics applied were simple and made it possible to calculate in an easy way the affinity and the activity of agonists as well as the affinity of antagonists. Looking back it is most remarkable that the ideas about receptor activation have been developed during a period of about 75 years, when no real information on the biochemical nature of receptors was available, not to speak about the molecular mechanisms involved in the generation or transfer of a signal. In the Introduction to the book Molecular Pharmacology (6) a receptor was compared with a beautiful lady; you may write a letter to her, sometimes she answers but she never shows up, though some day she may do so. Moreover, during a conference of the NY Academy of Sciences in 1967 Ariëns admitted in a very clear way: "when speaking about receptors I am talking about something I do not know anything about" (10) .
It seems that a medicinal chemist (Nauta) and not a pharmacologist, has proposed in 1968 for the first time that a GPCR family member might be a protein adopting a helical conformation, using the receptor for histamine as his model (11) Using this purely hypothetical model reversible interactions between a ligand and the amino acid side chains of the receptor protein were proposed to be involved in the binding of both agonists and antagonists ( Figure 1A ).
From GPCR gene cloning to constitutive, agonist-independent signaling and inverse agonists
With the introduction of the molecular biology in the area of G-protein coupled receptors, it lasted until 1986 before it became clear that the ideas of Nauta were quite close to reality (12). We now have high-resolution X-ray structures of at least one GPCR (figure 1B), rhodopsin {Palczewski, 2000 #4404;Li, 2004 #4403} available and a wealth of information on the structure-function relationships of various GPCRs (13) , including drug binding and GPCR activation (see section 2), has been gathered. In addition, genome sequencing projects have permitted to classify the human GPCR sequences into five main families: rhodopsin (Class A or family 1), secretin (Class B or family 2), glutamate (Class C or family 3), adhesion, and frizzled/taste2 (14) . The rhodopsin family is the largest and is subdivided in four main groups (α, β, γ, δ) with 13 sub-branches (α: prostaglandin, amine, opsin, melatonin, MECA; β: peptides; γ: SOG, MCH, chemokine; δ: MAS, glycoprotein, purine, olfactory). These groups include orphan GPCRs, receptors for which the ligand and the (patho)physiological function remain unknown. Specialized databases of GPCRs can be found at http://www.gpcr.org/7tm (15) and http://www.iuphar-db.org (16).
Our currents insights in GPCR activation have in the last years strongly relied on the notion that single point mutations could render GPCRs constitutively active, i.e. could signal without the presence of the respective agonist (17-19). At the same time, all these studies have also led to the general concept that constitutive GPCR signaling is an intrinsic property of most (if not all) GPCR family members and that either GPCR ligands or single point mutations can change the equilibrium between inactive and active receptor states (18) (19) (20) . Looking back, it is interesting to notice that already years before this general acceptance, research with only limited tools had provided convincing experimental evidence for constitutive GPCR signaling. In 1989 Costa and Herz started a shift in the paradigm on drug action with a paper, describing antagonists with negative intrinsic activity at wild type delta opioid receptors, endogenously expressed in NG108-15 neuroblastoma cells (21). In this paper, delta antagonists inhibited the basal GTPase activity with differential negative intrinsic activity and for the first time GPCR pharmacology clearly was faced with intrinsic drug activity going from 1 for agonists to -1 for antagonists with negative efficacy (now also referred to as inverse agonists). Many studies with either wild type or mutant GPCRs have thereafter confirmed the fact that GPCR proteins can signal in an agonist-independent, constitutive way and this has been extensively reviewed before (19, 22) . The notion of constitutive GPCR activity and the bidirectional modulation of GPCR activity by ligands has led to the introduction of a simple two-state model of GPCR action. In this model a GPCR protein can shift spontaneously between an inactive R to an active R* conformation (23-25). GPCR agonists shift the equilibrium to the active R* state, whereas inverse agonists favors the inactive R state. The two-state model also explains the observations that some antagonists do not affect constitutive GPCR signaling, since these neutral antagonists are considered not to affect the thermodynamic equilibrium between the different protein conformations. The two-state model and the concept of inverse agonism are now generally accepted and have been included in general pharmacology textbooks.
Constitutive GPCR activity of wild type GPCRs
As discussed above, the concept of constitutive activity was more or less generally accepted following convincing data sets obtained with various constitutively active mutant (CAM) GPCRs, which were generated in the lab. Yet, with the increased efforts in this area it has become clear that many wild type GPCRs also show considerable levels of constitutive activity. This has recently been systematically reviewed by Seifert and Wenzel-Seifert (19) and will therefore only be briefly discussed in this review.
For more than 60 wild type GPCRs from the class A, B and C families constitutive activity has now been documented (19). In particular the GPCRs encoded by herpesviruses exhibit constitutive activity, providing valuable information on this phenomenon that has been linked to the development of disease (see section 3) (26, 27). Especially the availability of recombinant expression systems has been instrumental in this recognition. The extent of constitutive GPCR activity depends on the expression level of the respective receptor and the cellular context (19). Constitutive GPCR activity might e.g. be boosted by increased expression of G proteins or additional downstream effector molecules (19). Nevertheless, for several GPCRs constitutive activity has been observed in native tissue or cells (19) . Prominent examples are the histamine H 3 receptor (28, 29) and the melanocortin MCR 1 and MCR 4 receptors, for which endogenous inverse agonists seem to be essential for a proper homeostasis (see also section 3) (30).
For many of the constitutively active GPCRs also inverse agonists have been identified (19). Most of the compounds that were previously characterized as competitive antagonists with intrinsic activities of 0, now turn out to be inverse agonists with negative intrinsic activities between -1 and 0. in heart failure seems to be due to its inverse agonist properties as the neutral antagonists bucindolol is not effective (20, 40) . These studies indicate that in certain conditions the therapeutic outcome of inverse agonists and neutral antagonists can indeed be different. In this respect, one also has to consider that long-term exposure to inverse agonists has been found to lead to upregulation of receptors, which might not always be beneficial and a potential reason for e.g. the development of treatment tolerance (37, 41, 42).
Structural aspects of (constitutive) GPCR activation.
In contrast to the wealth of available pharmacological data, structural information on GPCRs is still scarce. To date, the only crystal structure available is that of the inactive state of bovine rhodopsin (43, 44). Five structures of rhodopsin are available at the Protein Data Bank, at resolutions of 2.8 Å (PDB identifiers 1F88 and 1HZX), 2.65 Å (1GZM), 2.6 Å (1L9H), and 2.2 Å (1U19). Rhodopsin is formed by an extracellular Nterminus of four β-strands, seven transmembrane helices (TM 1 to TM 7) connected by alternating intracellular (I1 to I3) and extracellular (E1 to E3) hydrophilic loops, a disulfide bridge between E2 and TM3, and a cytoplasmic C-terminus containing an α- This section describes the different motifs that are involved in GPCR activation. This information will be used to explain the properties of naturally occurring GPCR mutants in section 3.
The ionic lock.
The interaction between R at position 3. 
Intracellular helix 8.
The recent X-ray structure of rhodopsin, revealed the presence of a highly conserved helix 8, suggested to be implicated in G protein coupling (43, 57). Figure 
The hydrophobic asparagine cage.
Alike to the arginine cage, N7.49 is also located in a cage, restraining its conformation towards TM6 in the inactive state, formed by conserved hydrophobic amino acids at 
Molecular basis of (inverse) agonism.
Many wild-type GPCRs display only moderate constitutive activity under normal conditions and can be significantly activated by addition of agonists. However, GPCRs can in general easily be modified to display enhanced basal activity and often this constitutive activity can be linked to diseases (17, 19) (see section 3). In this respect, inverse agonists are potentially important therapeutics in the treatment of diseases caused by constitutive activity-inducing mutations of the WT receptor.
The motifs described in sections 2.1-2.8 appear crucial determinants for the molecular basis of both agonism as well as inverse agonism. The processes initiated by the recognition of the extracellular ligand by the receptor depends to a large extent on the type of receptor, since they can be activated by a wide range of extracellular ligands, including small neurotransmitters to large hormones. Each subfamily has most likely developed specific structural motifs that allow the receptor to accommodate and respond to its cognate ligand. However, it seems reasonable to propose that in W6.48-containing 
Pathophysiological consequences of naturally occurring constitutively active GPCR variants.
With the recognition of constitutive GPCR activity and the notion that GPCR binding and signaling can be strongly affected by a single point mutation, GPCR pharmacogenomics recently obtained a lot of attention. For a variety of GPCRs, point mutations have been convincingly linked to human disease. In this section, we will review the present knowledge on naturally occurring mutant GPCRs involved in human disease and linked to constitutive activity. Moreover, we will try to explain the GPCR phenotype in relation to the presented structural motifs that are thought to be involved in GPCR activation.
Class A GPCRs

Rhodopsin
Vision under dim-light conditions by retinal rod photoreceptor cells is mediated by the visual pigment rhodopsin. Rhodopsin consists of the apoprotein opsin, a class A GPCR, to which an 11-cis-retinylidene chromophore is covalently bound through a protonated 
Glycoprotein hormone receptors
The thyroid-stimulating hormone receptor (TSHR), luteinizing hormone/chorionic gonadotropin receptor (LHCGR), and follicle-stimulating hormone receptor (FSHR), form the subfamily of glycoprotein hormone receptors (GpHRs) (87) . These receptors distinguish themselves from other class A GPCRs (16) by having a large N-terminal exodomain (NTED), which constitutes the selective hormone binding site (88) (89) (90) (91) .
Disease-causing CAMs have been found for all three members of this subfamily.
Interestingly, the TSHR is more susceptible to natural occurring CAMs than the LHCGR and FSHR (92).
Thyroid-stimulating hormone receptor
The thyroid regulates overall body metabolism by secreting thyroid hormones. Pituitary- 
Luteinizing hormone receptor
The development of the testis and external male genitalia is dependent on testosterone production by Leydig cells (97). During fetal development the proliferation, differentiation and testosterone production of these cells is induced by LHCGR signaling in response to placental-derived chorionic gonadotropin (CG In fact, mutational analysis revealed a direct relation between the level of constitutive activity and the responsiveness to promiscuous hormones (49).
Hitherto, patients with nonautoimmune hyperthyroidism receive treatment with antithyroid drugs (e.g. carbimazole), that interferes with thyroid hormone synthesis.
Although antithyroid drugs are efficient in controlling hyperthyroidism, they do not prevent thyroid enlargement (116) . Consequently, antithyroidal drug therapy is usually followed by thyroidectomy. FMPP is currently controlled by either inhibiting adrenal and testicular androgen biosynthesis using the P450 cytochrome inhibitor ketanazole, or combined administration of an androgen receptor antagonist (spironolactone) and aromatase inhibitor (testolactone) (117, 118) . Recently, specific non-peptide antagonists and agonists have been identified for the FSHR and LHCGR (119) (120) (121) (122) (123) (124) , with therapeutic potential for anticonception and assisted-reproduction, respectively. Hence, identification of non-peptide inverse agonists specifically inhibiting constitutive signaling of LHCGR, FSHR, or TSHR may therefore be a matter of time.
Growth hormone secretagogue receptor (GHSR) type 1a
The GHSR-1a receptor modulates growth hormone release upon activation by the peptide ghrelin, a potent hunger signal that stimulates appetite (125) . The loss of constitutive activity results in the expected phenotype with respect to growth, while this is not the case with respect to appetite and energy expenditure (131) . These findings indicate the existence of complex interactions and potential compensatory pathways to compensate for this loss of function in the GHSR-1a receptor. Possibly, activation of GPR39, recently deorphanized as the receptor for the peptide hormone obestatin, derived from the same gene as ghrelin, might account for this compensatory pathway. Activation of GPR39 has opposite effects on food intake and weight gain compared to stimulation of the GHSR-1a receptor (132).
Melanocortin receptors
The family of melanocortin receptors and the existence of endogenous inverse agonists acting at these receptors have greatly strengthened the concept of constitutive receptor activity and have further supported its physiological relevance. The melanocortin system, which controls pigmentation and body weight, encompasses a family of five receptors.
Both While no constitutively activating MC4R mutations have been reported to date from anorexia nervosa patients (142), one AgRP gene polymorphism has been associated with anorexia nervosa (143, 144) . In fact mutations in MC4R are thought to be the most common genetic cause of obesity. Besides the inactivating mutations within MCR4, there are also mutant MC4Rs found to be retained in the cytoplasm and poorly expressed (145) , or that respond poorly to MSH (146) . Yet, the overall influence of mutations in the MC4R on obesity is not clear, a variety of MC4R mutations found in non-obese individuals also exhibit loss-of-function characteristics, while impairment of cell surface expression for some mutant MC4R linked to the occurrence of obesity was not confirmed (142).
Virus-encoded GPCRs
Besides the naturally occurring GPCR variants described in previous sections 3.1.1-3.1.4
a relatively novel and intriguing class of GPCRs, encoded by the herpesviruses, exhibit marked constitutive activity. Altogether, the herpes-and poxviruses encode over 40
GPCRs, most of them displaying homology to chemokine receptors (147), known to be HCMV has been associated with chronic diseases including e.g. vascular diseases (167) and malignancies (168, 169) . Since the CMV-encoded receptors US28 and UL33
constitutively activate transcription factors, implicated in inflammatory events associated with e.g. atherosclerosis and tumorigenesis (170) , these receptors are believed to play a role in onset or progression of these HCMV-related pathologies. Recently, we have observed that expression of US28 induces transformation and tumorigenesis in vivo,
suggesting that US28 might act in a concerted manner with other oncogenic HCMVencoded proteins (171) to enhance tumorigenesis (172) . The use of constitutively inactive mutants, the development of adequate disease model systems and use of recently identified inverse agonists targeting the HCMV-encoded receptors (173) will serve as important tools to determine the (patho)physiological relevance of constitutive receptor activity of these receptors in vivo model systems.
Class B/C and Frizzled family GPCRs
In contrast to GPCRs belonging to the rhodopsin family of GPCRs (class A), little information is available on structural determinants involved in GPCR activation and inverse agonism of the class B/C and Frizzled GPCR families. Nonetheless, examples of natural occurring CAMs in these receptor families will be discussed below.
Parathyroid hormone (PTH)-related peptide (PTHrP) type 1 receptor (PTHR1)
The PTHR1 for PTH and PTHrP belongs to the class B GPCRs. This receptor is highly expressed in bone and kidney and mediates the PTH-dependent regulation of mineral ion homeostasis, including the circulating concentrations of calcium and phosphorous (174) .
Mutation of a histidine at the bottom of TM2 (H 
Smoothened
Smoothened is a GPCR that is thought to signal via families of heterotrimeric G proteins and possibly via non-G protein signaling pathways (182) Hence, modulators of smoothened activity appear promising for the treatment of a variety of cancers as well as psoriasis (188) (189) (190) (191) . Consequently, several smoothened modulators have recently been described (192) (193) (194) .
Concluding remarks
Not only mutational analysis of wild type GPCRs, but also those natural occurring CAMs that are associated with disease, have contributed to our knowledge on constitutive receptor activity. Specific conserved domains within the receptor appear essential in the regulation of (spontaneous) signaling. In particular, mutational changes near the interface at the bottom of TM3 or top of TM6 often result in increases of constitutive activity (19). Analogous to these observations, an agonist is believed to relieve the receptor from these intrinsic constraints, inducing a movement of the bottom of TM6 (47, 195) . Mutations in these regions are found in a number of GPCRs, e.g. of the glycoprotein family, that are associated with human diseases. Disruption of the constraint within those receptors, leads to constitutive receptor activity and consequently to the development of disease. In particular, in these cases the use of inverse agonists is in particular definitely the choice of treatment.
For some GPCRs, autoantibodies have been identified that recognize epitopes on the second, most variable, extracellular loop, causing pathologies (see for refs (20, 22) . The fact that the second extracellular loop seems to be in part implicated in constitutive activity of some receptors (68), might explain the observed effects of autoantibodies.
These antibodies appear indeed to influence receptor activity and some even display agonsitic activity (196) These figures were created using MolScript v2.1.1 (198) and Raster3D v2.5 (199) . 
